Conditions: Alzheimer's Disease Huntington's Disease
Keywords: oral single-dose 6-way crossover recreational drug users abuse potential pharmacodynamics safety
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 36
Healthy volunteers: no

Brief summary:
Dimebon will not exhibit abuse potential when compared to placebo or a positive control (alprazolam).

Detailed description:
The main purpose for this study is to determine whether dimebon exhibits abuse potential.

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None arm 5: None arm 6: None

Interventions: intervention 1: dimebon intervention 2: dimebon intervention 3: dimebon intervention 4: placebo intervention 5: alprazolam intervention 6: alprazolam
Intervention descriptions: intervention 1: Oral tablet; 20 mg dimebon, single dose intervention 2: Oral tablet; 40 mg dimebon, single dose intervention 3: Oral tablet; 60 mg dimebon, single dose intervention 4: Oral tablet or capsule; placebo, single dose intervention 5: Oral capsule; 1 mg alprazolam, single dose intervention 6: Oral capsule; 3 mg alprazolam, single dose

Protocol document: